Poseida Therapeutics press release (NASDAQ:PSTX): Q3 GAAP EPS of $0.21. Revenue of $71.7M (+666.8% Y/Y). The increases were primarily due to milestone recognition and an increase in reimbursed research and development expenses under the Roche Collaboration Agreement, and revenue recognized from the Astellas Strategic Agreements and Astellas Collaboration Agreement.
More on Poseida Therapeutics
Poseida: Interim P-BCMA-ALLO1 Data Bodes Well For Phase 1B Advancement Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024 Poseida struggles post market after phase 1 multiple myeloma CAR-T therapy data Seeking Alpha's Quant Rating on Poseida Therapeutics Historical earnings data for Poseida Therapeutics